ISONIAZID (isoniazid) by GenexGen is mechanism of action isoniazid inhibits the synthesis of mycoloic acids, an essential component of the bacterial cell wall.
Drug data last refreshed 1h ago · AI intelligence enriched 1mo ago
Isoniazid is a first-line oral tablet antibiotic that treats tuberculosis by inhibiting mycolic acid synthesis in the bacterial cell wall, rendering it bactericidal against actively growing Mycobacterium tuberculosis. It is a foundational therapy for TB treatment globally, often used in combination regimens.
Pre-launch status indicates a nascent commercial organization with limited team size; career opportunities will expand post-approval depending on market penetration and competitive positioning.
Mechanism of Action Isoniazid inhibits the synthesis of mycoloic acids, an essential component of the bacterial cell wall. At therapeutic levels isoniazid is bactericidal against actively growing intracellular and extracellular Mycobacterium tuberculosis organisms.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV
Evaluating Urine Isoniazid Testing to Detect Nonadherence to Tuberculosis Medications in India
Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients
Worked on ISONIAZID at GenexGen? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
GenexGen is hiring 2 roles related to this product
Working on isoniazid at GenexGen is a pre-launch opportunity to build a commercial franchise around a critical global health asset in TB treatment. Roles will emphasize market access, payer negotiations, and healthcare system partnerships rather than primary commercialization scale.